Confronto
Calcitonin (Lachs) vs. Pasireotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
47931-85-1
396091-73-9
Peso molecolare
3431.85 g/mol
1047.21 g/mol
Emivita
1 h
nessun dato
Sequenza
Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2nessun dato
Meccanismo d'azione
Calcitonin (Lachs)
Salmon calcitonin binds the calcitonin receptor, which is particularly densely expressed on bone-resorbing osteoclasts. The literature describes that receptor activation inhibits osteoclast activity and motility, thereby reducing bone resorption. This results in reduced release of calcium and phosphate from bone into the blood, which is regarded as the mechanistic basis for the calcium-lowering effect. The salmon variant binds the receptor more strongly and for longer than human calcitonin, which explains its higher potency. Central nervous system mechanisms are additionally discussed in relation to its pain effect in fractures, the basis of which is regarded in the literature as not fully elucidated.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
4
1
Effetti registrati
4
2
Contraddizioni aperte
1
0
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Calcitonin (Lachs) and Pasireotid?
- Calcitonin (Lachs) is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Calcitonin (Lachs): Salmon calcitonin is a synthetically produced 32-amino-acid peptide hormone that corresponds to the body's own calcitonin but exhibits higher biological potency than the human hormone. In the scientific literature it is studied in the context of inhibiting osteoclast-mediated bone resorption and lowering elevated calcium levels. It was historically broadly approved for the treatment of postmenopausal osteoporosis; following European safety reviews, however, its use was restricted. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Calcitonin (Lachs) or Pasireotid?
- The highest available evidence level is "RCT sull'uomo" for Calcitonin (Lachs) and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Calcitonin (Lachs) and Pasireotid in Germany and the United States?
- Germania: Calcitonin (Lachs) — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Calcitonin (Lachs) — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.